TMS

TMS ((E) -2,3',4,5'-tetramethoxystilbene) is a selective and competitive CYP1B1 inhibitor with an IC50 of 6 nM and a Ki value of 3 nM. TMS shows a lesser extent inhibitory effect on CYP1A1 (IC50=300 nM) and CYP1A2 (IC50=3.1 μM) . TMS is a methylated derivative of resveratrol and has anti-cancer activity[1][2][3].

Product Specifications

CAS Number

[24144-92-1]

Product Name Alternative

(E) -2,3',4,5'-tetramethoxystilbene

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TMS.html

Purity

99.40

Solubility

DMSO : ≥ 50 mg/mL

Smiles

COC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C(OC)=C1

Molecular Formula

C18H20O4

Molecular Weight

300.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Einem Lindeman T, et al. The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis. 2011 Sep;26 (5) :629-35.|[2]Jennings BL, et al. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2014 Apr;28 (2) :145-61.|[3]Sanghee Kim, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45 (1) :160-4.